Yasser Alatawi

816 total citations
45 papers, 526 citations indexed

About

Yasser Alatawi is a scholar working on Economics and Econometrics, Epidemiology and Clinical Psychology. According to data from OpenAlex, Yasser Alatawi has authored 45 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Economics and Econometrics, 7 papers in Epidemiology and 6 papers in Clinical Psychology. Recurrent topics in Yasser Alatawi's work include COVID-19 and Mental Health (6 papers), Pharmaceutical Practices and Patient Outcomes (6 papers) and Acute Ischemic Stroke Management (6 papers). Yasser Alatawi is often cited by papers focused on COVID-19 and Mental Health (6 papers), Pharmaceutical Practices and Patient Outcomes (6 papers) and Acute Ischemic Stroke Management (6 papers). Yasser Alatawi collaborates with scholars based in Saudi Arabia, United States and Egypt. Yasser Alatawi's co-authors include Richard A. Hansen, Fahad S. Alshehri, Badrah S. Alghamdi, Abdullah A. Alhifany, Jan Kavookjian, Jingjing Qian, Richard L. Berg, Peggy Peissig, Hashem O. Alsaab and Ning Cheng and has published in prestigious journals such as Frontiers in Microbiology, Sensors and International Journal of Environmental Research and Public Health.

In The Last Decade

Yasser Alatawi

35 papers receiving 509 citations

Peers

Countries citing papers authored by Yasser Alatawi

Since Specialization

Citations

This map shows the geographic impact of Yasser Alatawi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasser Alatawi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasser Alatawi more than expected).

Fields of papers citing papers by Yasser Alatawi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasser Alatawi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasser Alatawi. The network helps show where Yasser Alatawi may publish in the future.

Co-authorship network of co-authors of Yasser Alatawi

This figure shows the co-authorship network connecting the top 25 collaborators of Yasser Alatawi. A scholar is included among the top collaborators of Yasser Alatawi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasser Alatawi. Yasser Alatawi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The gut microbiome in diabetic patients with hepatocellular carcinoma: distinct bacterial compositional shifts after hepatitis C virus eradication 2026 ·Frontiers in Microbiology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Abdullah Alattar, Reem Alshaman, Yasser Alatawi, (unknown)	0
2	Assessing the effects of antidepressant use on stroke recurrence and related outcomes in ischemic stroke patients: a propensity score matched analysis 2025 ·Frontiers in Pharmacology ·Faisal F. Alamri, (unknown), Yasser Alatawi, (unknown), (unknown), (unknown), Ziyad S. Almalki, (unknown), (unknown), (unknown), Hussain Aldera, Vardan T. Karamyan	0
3	Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise 2025 ·Pharmaceuticals ·(unknown), Yasser Alatawi, Abdullah Alattar, Reem Alshaman, (unknown), ‏Helal F. Hetta	0
4	Effects of previous steroid treatment on ischemic stroke outcomes: a propensity score-matched hospital analysis 2025 ·Frontiers in Pharmacology ·Yasser Alatawi, (unknown), Abdullah A. Alhifany, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Faisal F. Alamri	0
5	A multicenter analysis to identify the risk factors for stroke recurrence and mortality within 1 year 2025 ·Frontiers in Neurology ·(unknown), (unknown), Yasser Alatawi, (unknown), (unknown), (unknown), Faisal F. Alamri	2
6	Insights into risk factors and outcomes of post-stroke seizures in Saudi Arabia: a multicenter analysis 2024 ·Metabolic Brain Disease ·(unknown), Yasser Alatawi, Raju Suresh Kumar, (unknown), (unknown), (unknown), (unknown), Khalid Al Sulaiman, Faisal F. Alamri	4
7	Evaluating preceptorship during advanced pharmacy practice experiences in Saudi Arabia: A Cross-Sectional Study 2024 ·Saudi Pharmaceutical Journal ·(unknown), (unknown), Yasser Alatawi, Abdullah A. Alhifany	1
8	Gap between recognition and response to stroke scenarios among Saudi population: Cross-sectional survey study 2023 ·Journal of Stroke and Cerebrovascular Diseases ·(unknown), (unknown), Yasser Alatawi, Badrah S. Alghamdi	0
9	PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers 2023 ·BMC Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Faisal Azam, (unknown), Lobna Gharaibeh, Yasser Alatawi, (unknown), Hashem O. Alsaab	25
10	Evaluation of Impact of a Pharmacist-Led Educational Campaign on Disease Knowledge, Practices and Medication Adherence for Type-2 Diabetic Patients: A Prospective Pre- and Post-Analysis 2022 ·International Journal of Environmental Research and Public Health ·Yusra Habib Khan, Abdulaziz Ibrahim Alzarea, Nasser Hadal Alotaibi, Ahmed D. Alatawi, (unknown), Abdullah Salah Alanazi, Muhammad Hammad Butt, (unknown), Sameer Alshehri, Yasser Alatawi, Tauqeer Hussain Mallhi	15
11	Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials 2022 ·Saudi Pharmaceutical Journal ·Abdullah A. Alhifany, (unknown), Yasser Alatawi, Saad Ullah Malik, Thamer A. Almangour, Ali F. Altebainawi, Thamir M. Alshammari, (unknown), (unknown), Fahad S. Alshehri, Ejaz Cheema	0
12	Evaluation of participation and performance indicators in a breast cancer screening program in Saudi Arabia 2022 ·Saudi Medical Journal ·Yasser Alatawi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tarik Alafif, (unknown), (unknown), (unknown), (unknown), (unknown)	2
13	Psychological Distress During COVID-19 Curfews and Social Distancing in Saudi Arabia: A Cross-Sectional Study 2022 ·Frontiers in Public Health ·Badrah S. Alghamdi, Yasser Alatawi, Fahad S. Alshehri, Haythum O. Tayeb, (unknown), (unknown)	12
14	Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study 2022 ·Cureus ·(unknown), Yasser Alatawi, (unknown), (unknown), (unknown), (unknown), Mohammed Jaffal, (unknown), (unknown), (unknown)	3
15	Melatonin Improves Short-Term Spatial Memory in a Mouse Model of Alzheimer’s Disease 2021 ·PubMed ·(unknown), Fahad S. Alshehri, Maher Kurdi, Yasser Alatawi, Badrah S. Alghamdi	23
16	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study 2021 ·International Journal of General Medicine ·(unknown), Ahmed S. Ali, (unknown), Yasser Alatawi, Sultan Alotaibi, Abdullah A. Alhifany, (unknown), (unknown), (unknown), (unknown), Aziza Alrafiah	8
17	Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis 2019 ·Supportive Care in Cancer ·Abdullah A. Alhifany, Ali McBride, Abdulaali R. Almutairi, Ejaz Cheema, (unknown), Yasser Alatawi, (unknown), Hani M. Babiker, Karen MacDonald, Matti Aapro, Ivo Abraham	4
18	Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS) 2017 ·Clinical Drug Investigation ·(unknown), Yasser Alatawi, Ning Cheng, Jingjing Qian, Peggy Peissig, Richard L. Berg, David C. Page, Richard A. Hansen	11
19	Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) 2017 ·Epilepsy Research ·(unknown), Yasser Alatawi, Ning Cheng, Jingjing Qian, (unknown), Peggy Peissig, Richard L. Berg, David Page, Richard A. Hansen	22
20	The association between health beliefs and medication adherence among patients with type 2 diabetes 2015 ·Research in Social and Administrative Pharmacy ·Yasser Alatawi, Jan Kavookjian, (unknown), (unknown)	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact